logo-loader
viewZacks Small-Cap Research

Zacks Investment Research analyst covers current trends in biotech industry

Zacks Investment Research Inc Biotechnology Analyst John Vandermosten speaks to Proactive Investors at the MicroCap Conference in New York. 

Vandermosten commented on Antares Pharma (NASDAQ:ATRS), and how the biotech's testosterone drug has just gained FDA approval.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Duke Royalty Limited 'doing just fine' by maintaining a diversified...

Duke Royalty Limited (LON:DUKE) CEO Neil Johnson tells Proactive the provider of alternative capital solutions is 'doing just fine' and withstanding the current pandemic situation by maintaining a diversified portfolio. Johnson says Duke, which recently reported a trading update, has exposure...

3 days, 12 hours ago

2 min read